Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy.

Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy. Oncology (Williston Park). 2010 Aug; 24(9):839-44.

View in: PubMed

© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.